Biblio
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer. Mol Cancer. 2024;23(1):3.
. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. Mol Cancer. 2023;22(1):6.
. FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway. Sci China Life Sci. 2023.
KK-LC-1 as a therapeutic target to eliminate ALDH stem cells in triple negative breast cancer. Nat Commun. 2023;14(1):2602.
A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44CD24 enriched breast cancer stem-like cells. Drug Resist Updat. 2022;66:100903.
Targeting SOST using a small-molecule compound retards breast cancer bone metastasis. Mol Cancer. 2022;21(1):228.